NCT01613209View on ClinicalTrials.gov

Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine

PHASE3CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

October 31, 2012

Conditions
Hypertension
Interventions
DRUG

Candesartan cilexetil

candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,

DRUG

Olmesartan/Amlodipin

olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)

Trial Locations (12)

12043

Praxis Dr. Zemmrich, Berlin

26180

Praxis Dr. Loddo, Rastede

38836

Praxis Dr. Reimer, Anderbeck

45138

Praxis Koßler-Wiesweg, Essen

49661

St.-Josefs-Hospital, Cloppenburg

51429

Praxis Dr. Heinz, Bergisch Gladbach

65929

Praxis Dr. Rövenich, Frankfurt

67061

Praxis Dr. Pitule, Ludwigshafen

99444

Praxis Dr. Biedermann, Blankenhain

99510

Praxis Dr. Strzata, Kapellendorf

04316

Praxis Dr. Paschmionka, Leipzig

01129

Praxis Dr. Pohl, Dresden

All Listed Sponsors
lead

Institut für Pharmakologie und Präventive Medizin

NETWORK

NCT01613209 - Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine | Biotech Hunter | Biotech Hunter